Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Citations, Citation Indicators, and Research Quality: An Overview of Basic Concepts and Theories
2019 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Effective expansion of alloantigen-specific Foxp3 + CD25 + CD4 + regulatory T cells by dendritic cells during the mixed leukocyte reaction
2006 StandoutNobel
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
2002
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Metric Power and the Academic Self: Neoliberalism, Knowledge and Resistance in the British University
2018 Standout
First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation
2012
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality
2015 StandoutNobel
Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors
2005
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
2012 Standout
Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma
2005
Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease
2002
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
CD25+CD4+ T cells in human cord blood: an immunoregulatory subset with naive phenotype and specific expression of forkhead box p3 (Foxp3) gene
2004 StandoutNobel
Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome
2005
Long‐term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma
2009
Photopheresis in paediatric patients with drug‐resistant chronic graft‐versus‐host disease
1997
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS
2001
Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric Oxide
2008 Standout
Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept
2005
Myelodysplastic Syndromes
2004
Control of Autoimmunity by Naturally Arising Regulatory CD4+ T Cells
2003 StandoutNobel
Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
2010
Vascular disorders of the liver # †
2008 Standout
Primary central nervous system lymphoma: The role of consolidation treatment after a complete response to high‐dose methotrexate‐based chemotherapy
2008
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes
2004
Chronic graft-versus-host disease
2003 Standout
Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly
2011
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Graft-versus-host disease
2009 Standout
PATHOPHYSIOLOGY AND TREATMENT OF GRAFT-VERSUS-HOST DISEASE
1999
Autologous Stem Cell Transplantation in Myelodysplastic Syndromes
2007
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Clinical trials of antibody therapy
2000
Hematopoietic Stem-Cell Transplantation
2006 Standout
Regulatory T cells in transplantation tolerance
2003 StandoutNobel
Cardioprotective effect of metoprolol and enalapril in doxorubicin‐treated lymphoma patients: A prospective, parallel‐group, randomized, controlled study with 36‐month follow‐up
2010
Primary brain tumours in adults
2012 Standout
Monoclonal antibodies for the prevention and treatment of graft-versus-host disease
2003
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study
2008
Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells
2004 StandoutNobel
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly
2007
Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron
2009 Standout
Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?
2010
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 Standout
Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis
2006
Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
2015
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Primary CNS Lymphoma in Immunocompetent Patients
2009
High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation
2002
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
A Challenge to Metrics as Evidence of Scholarity
2011
Anthracycline cardiotoxicity
2006
Human mesenchymal stem cells modulate allogeneic immune cell responses
2004 Standout
Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma
2004 Standout
ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context
2012 Standout
Treatment of Hepatic Venocclusive Disease With Recombinant Human Tissue Plasminogen Activator and Heparin in 42 Marrow Transplant Patients
1997
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
2006 Standout
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease
2020
Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses.
2005
CD4+regulatory cells as a potential immunotherapy
2005 StandoutNobel
Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
2004
Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
2008
Inhibitors of the anaplastic lymphoma kinase
2012
Dendritic cells expand antigen‐specific Foxp3+CD25+CD4+ regulatory T cells including suppressors of alloreactivity
2006 StandoutNobel
Regulatory T cell and autoimmune diseases
2005 StandoutNobel
CD4+CD25+Foxp3+ T Cells and CD4+CD25−Foxp3+ T Cells in Aged Mice
2006 StandoutNobel
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Cardiotoxicity of Antitumor Drugs
2008
Tolerogenic Dendritic Cells
2003 StandoutNobel
DORA: San Francisco Declaration on Research Assessment (May 2013)
2014
The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality
2002
Dendritic cells induce antigen-specific regulatory T cells that prevent graft versus host disease and persist in mice
2011 StandoutNobel
Novel therapeutics for the treatment of graft-versus-host disease
2002
Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's Lymphoma
2008
Ranking Games
2014
Elicitation of structure-specific antibodies by epitope scaffolds
2010 StandoutNobel
B7 Expression on T Cells Down-Regulates Immune Responses through CTLA-4 Ligation via R-T Interactions
2004 StandoutNobel
Large-scale assessment of research outputs through a weighted combination of bibliometric indicators
2016 StandoutNobel
The role of extracorporeal photopheresis in the management of cutaneous T‐cell lymphoma, graft‐versus‐host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society
2017
Works of A. Brion being referenced
Autologous stem cell transplantation for anaplastic large‐cell lymphomas: results of a prospective trial
2000
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes
1999
Early cardiotoxicity of the CHOP regimen in aggressivenon-Hodgkin’s lymphoma
2003
PHOTOTHERAPY IN THE TREATMENT OF CUTANEOUS GRAFT-VERSUS-HOST DISEASE
1995
Measuring research quality using the journal impact factor, citations and ‘Ranked Journals’: blunt instruments or inspired metrics?
2009
Prevention of veno-occlusive disease of the liver after bone marrow transplantation: heparin or no heparin? [letter; comment]
1992
Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study.
1995
Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma
2014
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group
2006